keyword
MENU ▼
Read by QxMD icon Read
search

Echinocandin

keyword
https://www.readbyqxmd.com/read/28104387/impact-of-echinocandin-on-prognosis-of-proven-invasive-candidiasis-in-icu-a-post-hoc-causal-inference-model-using-the-amarcand2-study
#1
Sébastien Bailly, Olivier Leroy, Elie Azoulay, Philippe Montravers, Jean-Michel Constantin, Hervé Dupont, Didier Guillemot, Olivier Lortholary, Jean-Paul Mira, Pierre-François Perrigault, Jean-Pierre Gangneux, Jean-François Timsit
OBJECTIVE: guidelines recommend first-line systemic antifungal treatment (SAT) with echinocandins in invasive candidiasis (IC), especially in critically ill patients. This study aimed at assessing the impact of echinocandins compared to azoles as initial SAT on the 28-day prognosis in adult ICU patients. METHODS: From the prospective multicenter AmarCAND2 cohort (835 patients), we selected those with documented IC and treated with echinocandins (ECH) or azoles (AZO)...
January 16, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28099778/pseudozyma-and-other-non-candida-opportunistic-yeast-bloodstream-infections-in-a-large-stem-cell-transplant-center
#2
Anupam Pande, Lemuel R Non, Rizwan Romee, Carlos A Q Santos
INTRODUCTION: Non-Candida opportunistic yeasts are emerging causes of bloodstream infection (BSI) in immunocompromised hosts. However, their clinical presentation, management, and outcomes in stem cell transplant (SCT) recipients are not well described. CASE REPORT AND REVIEW: We report the first case to our knowledge of Pseudozyma BSI in a SCT recipient. He had evidence of cutaneous involvement, which has not been previously described in the literature. He became infected while neutropenic and receiving empiric micafungin, which is notable because Pseudozyma is reported to be resistant to echinocandins...
January 18, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28096163/large-scale-evaluation-of-in-vitro-amphotericin-b-triazole-and-echinocandin-activity-against-coccidioides-species-from-united-states-institutions
#3
George R Thompson, Bridget M Barker, Nathan P Wiederhold
Large-scale testing of Coccidioides isolates has not previously been performed, nor has the frequency of clinical isolates with elevated amphotericin B or triazole MICs been evaluated. Coccidioides isolates (n=581) underwent antifungal susceptibility testing. Elevated MIC values were observed for: fluconazole (MIC ≥16 μg/ml, 37.3% of isolates; ≥32 μg/ml, 7.9%), itraconazole (1.0% ≥2 μg/ml), posaconazole (1.0% ≥1 μg/ml), and voriconazole (1.2% ≥2 μg/ml). However mould-active triazoles exhibited low MICs for the majority of isolates tested...
January 17, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28080986/clinical-implications-of-globally-emerging-azole-resistance-in-aspergillus-fumigatus
#4
REVIEW
Jacques F Meis, Anuradha Chowdhary, Johanna L Rhodes, Matthew C Fisher, Paul E Verweij
Aspergillus fungi are the cause of an array of diseases affecting humans, animals and plants. The triazole antifungal agents itraconazole, voriconazole, isavuconazole and posaconazole are treatment options against diseases caused by Aspergillus However, resistance to azoles has recently emerged as a new therapeutic challenge in six continents. Although de novo azole resistance occurs occasionally in patients during azole therapy, the main burden is the aquisition of resistance through the environment. In this setting, the evolution of resistance is attributed to the widespread use of azole-based fungicides...
December 5, 2016: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
https://www.readbyqxmd.com/read/28072553/decreased-killing-activity-of-micafungin-against-candida-guilliermondii-candida-lusitaniae-and-candida-kefyr-in-the-presence-of-human-serum
#5
Qasem Saleh, Renátó Kovács, Gábor Kardos, Rudolf Gesztelyi, Tamás Kardos, Aliz Bozó, László Majoros
Currently, echinocandins are first-line drugs for treatment of invasive candidiasis. However, data on how serum influences killing activity of echinocandins against uncommon Candida species are limited. Therefore, the killing activity of micafungin in RPMI-1640 and in 50% serum was compared against Candida guilliermondii, Candida lusitaniae, and Candida kefyr. Minimum inhibitory concentration (MIC) ranges in RPMI-1640 were 0.5-1, 0.12-0.25, and 0.06-0.12 mg/L, respectively. In 50% serum, MICs increased 32- to 256-fold...
January 10, 2017: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/28065893/pan-azole-resistant-candida-tropicalis-carrying-homozygous-erg11-mutations-at-position-k143r-a-new-emerging-superbug
#6
Mariana I D S Xisto, Rita D F Caramalho, Débora A S Rocha, Antonio Ferreira-Pereira, Bettina Sartori, Eliana Barreto-Bergter, Maria L Junqueira, Cornelia Lass-Flörl, Michaela Lackner
OBJECTIVES: Candidaemia is a public health problem mainly in hospitalized individuals worldwide. In Brazil, Candida albicans is the most prevalent species that causes candidaemia, followed by Candida tropicalis and Candida parapsilosis Few data on the abundance of antifungal resistance are available for Latin America. METHODS: We analysed the frequency of azole and echinocandin resistance in Candida isolates (n = 75) collected between 2012 and 2014 at the University Hospital of Federal University of Juiz de Fora (Brazil)...
January 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28058254/special-issue-novel-antifungal-drug-discovery
#7
Maurizio Del Poeta
This Special Issue is designed to highlight the latest research and development on new antifungal compounds with mechanisms of action different from the ones of polyenes, azoles, and echinocandins. The papers presented here highlight new pathways and targets that could be exploited for the future development of new antifungal agents to be used alone or in combination with existing antifungals. A computational model for better predicting antifungal drug resistance is also presented.
2016: Journal of Fungi (Basel, Switzerland)
https://www.readbyqxmd.com/read/28052853/activity-of-a-long-acting-echinocandin-cd101-and-seven-comparator-antifungal-agents-tested-against-a-global-collection-of-contemporary-invasive-fungal-isolates-in-the-sentry-2014-antifungal-surveillance-program
#8
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Mariana Castanheira
The activity of CD101 and comparators was evaluated against 606 invasive fungal isolates collected worldwide during 2014 using the CLSI method. All C. albicans (n=251), C. tropicalis (n=51), C. krusei (n=16), and C. dubliniensis (n=11) were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or wild type to other echinocandins. Five C. glabrata (n=100) displayed CD101 MIC values of 1-4 μg/ml, elevated caspofungin (2->8 μg/ml), anidulafungin (2-4 μg/ml), and micafungin (2-4 μg/ml) MICs, and carried mutations on fks1/fks2 C...
January 4, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28050365/caspofungin-mic-distribution-amongst-commonly-isolated-candida-species-in-a-tertiary-care-centre-an-indian-experience
#9
Shashir Wanjare, Rajarshi Gupta, Preeti Mehta
INTRODUCTION: Emergence of Candida species resistant to Amphotericin B and triazole has led to use of echinocandins, mostly caspofungin in the management of invasive candidiasis. There are some published reports of caspofungin resistance in Candida species yet no studies on caspofungin susceptibility pattern of Candida species exist in Indian setup. AIM: To carry out the antifungal susceptibility of Candida isolates against caspofungin. MATERIALS AND METHODS: In a retrospective study at a tertiary care teaching hospital, 60 preserved Candida isolates from inpatients of invasive candidiasis obtained over a period of 6 months from January 2015 to June 2015 were subjected to antifungal susceptibility to caspofungin and the Minimum Inhibitory Concentrations (MICs) of Candida species to caspofungin were determined by Epsilometer test (E-test)...
November 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28050053/aspergillus-section-nidulantes-formerly-emericella-polyphasic-taxonomy-chemistry-and-biology
#10
A J Chen, J C Frisvad, B D Sun, J Varga, S Kocsubé, J Dijksterhuis, D H Kim, S-B Hong, J Houbraken, R A Samson
Aspergillus section Nidulantes includes species with striking morphological characters, such as biseriate conidiophores with brown-pigmented stipes, and if present, the production of ascomata embedded in masses of Hülle cells with often reddish brown ascospores. The majority of species in this section have a sexual state, which were named Emericella in the dual name nomenclature system. In the present study, strains belonging to subgenus Nidulantes were subjected to multilocus molecular phylogenetic analyses using internal transcribed spacer region (ITS), partial β-tubulin (BenA), calmodulin (CaM) and RNA polymerase II second largest subunit (RPB2) sequences...
June 2016: Studies in Mycology
https://www.readbyqxmd.com/read/28039272/micafungin-alters-the-amino-acid-nucleic-acid-and-central-carbon-metabolism-of-candida-albicans-at-subinhibitory-concentrations-novel-insights-into-mechanisms-of-action
#11
Aspasia Katragkou, Michael Williams, Sandi Sternberg, Dennis Pantazatos, Emmanuel Roilides, Thomas J Walsh
BACKGROUND: Echinocandins are an important class of antifungal agents in the treatment of invasive candidiasis. However, little is known about the metabolomic effects of echinocandins on Candida We therefore performed LC-high-resolution MS (LC-HRMS)-based metabolomics profiling of the response of Candida albicans cells to increasing concentrations of micafungin to determine the metabolic response of Candida to micafungin subinhibitory injury. METHODS: Isolates of C...
December 30, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28018323/genetic-drivers-of-multidrug-resistance-in-candida-glabrata
#12
Kelley R Healey, Cristina Jimenez Ortigosa, Erika Shor, David S Perlin
Both the incidence of invasive fungal infections and rates of multidrug resistance associated with fungal pathogen Candida glabrata have increased in recent years. In this perspective, we will discuss the mechanisms underlying the capacity of C. glabrata to rapidly develop resistance to multiple drug classes, including triazoles and echinocandins. We will focus on the extensive genetic diversity among clinical isolates of C. glabrata, which likely enables this yeast to survive multiple stressors, such as immune pressure and antifungal exposure...
2016: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28011902/ecil-6-guidelines-for-the-treatment-of-invasive-candidiasis-aspergillosis-and-mucormycosis-in-leukemia-and-hematopoietic-stem-cell-transplant-patients
#13
Frederic Tissot, Samir Agrawal, Livio Pagano, Georgios Petrikkos, Andreas H Groll, Anna Skiada, Cornelia Lass-Flörl, Thierry Calandra, Claudio Viscoli, Raoul Herbrecht
The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematological malignancies or hematopoietic stem cell transplantation recipients. Meetings are held every two years since 2005 and evidence-based recommendations are elaborated after evaluation of the literature and discussion among specialists of nearly all European countries. In this manuscript, the ECIL group presents the 2015-update of the recommendations for the targeted treatment of invasive candidiasis, aspergillosis and mucormycosis...
December 23, 2016: Haematologica
https://www.readbyqxmd.com/read/28004589/an-update-on-the-safety-and-interactions-of-antifungal-drugs-in-stem-cell-transplant-recipients
#14
Corrado Girmenia, Anna Paola Iori
Invasive fungal diseases (IFDs) are a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). Improvement in the management of IFDs have been achieved with the availability of new effective and safe antifungal drugs, however, many of these newer treatments have some limitations in their variable toxicity and unique predisposition for pharmacokinetic drug-drug interactions. Areas covered: This article is an update of a previous review published in this journal evaluating the safety profile of the antifungal drugs...
December 26, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27995055/recurrent-episodes-of-candidemia-due-to-candida-glabrata-candida-tropicalis-and-candida-albicans-with-acquired-echinocandin-resistance
#15
Marine Grosset, Marie Desnos-Ollivier, Cendrine Godet, Catherine Kauffmann-Lacroix, France Cazenave-Roblot
Mixed fungal infection and acquired echinocandin resistance of Candida spp. remain infrequent. In this study we have reported the case of a patient hospitalized for tuberculosis who experienced multiple infections due to three common Candida species (C. albicans, C. glabrata, C. tropicalis). Furthermore, consecutive isolates from blood cultures and heart valve were found resistant to azoles (C. tropicalis) and to echinocandin with either novel (C. tropicalis) or previously described (C. albicans) missense mutations in the Fks gene...
December 2016: Medical Mycology Case Reports
https://www.readbyqxmd.com/read/27994475/isavuconazole-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis-current-evidence-safety-efficacy-and-clinical-recommendations
#16
REVIEW
Suganthini Krishnan Natesan, Pranatharthi H Chandrasekar
The majority of invasive mold infections diagnosed in immunocompromised cancer patients include invasive aspergillosis (IA) and mucormycosis. Despite timely and effective therapy, mortality remains considerable. Antifungal agents currently available for the management of these serious infections include triazoles, polyenes, and echinocandins. Until recently, posaconazole has been the only triazole with a broad spectrum of anti-mold activity against both Aspergillus sp. and mucorales. Other clinically available triazoles voriconazole and itraconazole, with poor activity against mucorales, have significant drug interactions in addition to a side effect profile inherent for all triazoles...
2016: Infection and Drug Resistance
https://www.readbyqxmd.com/read/27988485/simultaneous-emergence-of-multidrug-resistant-candida-auris-on-3-continents-confirmed-by-whole-genome-sequencing-and-epidemiological-analyses
#17
Shawn R Lockhart, Kizee A Etienne, Snigdha Vallabhaneni, Joveria Farooqi, Anuradha Chowdhary, Nelesh P Govender, Arnaldo Lopes Colombo, Belinda Calvo, Christina A Cuomo, Christopher A Desjardins, Elizabeth L Berkow, Mariana Castanheira, Rindidzani E Magobo, Kauser Jabeen, Rana J Asghar, Jacques F Meis, Brendan Jackson, Tom Chiller, Anastasia P Litvintseva
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates...
January 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27970824/utilisation-and-dosage-patterns-of-intravenous-echinocandins-for-treatment-of-invasive-fungal-infections-within-hospitals-in-england
#18
H B Ahir, E McCann, S Robertson, S Patel, E Yu, R Tham
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27956419/fungal-cyp51-inhibitors-vt-1161-and-vt-1129-exhibit-strong-in-vitro-activity-against-candida-glabrata-and-c-krusei-isolates-clinically-resistant-to-azole-and-echinocandin-antifungal-compounds
#19
W A Schell, A M Jones, E P Garvey, W J Hoekstra, R J Schotzinger, B D Alexander
In vitro activity of fungal CYP51 inhibitors VT-1161 and VT-1129 was determined for Candida glabrata (N=34) and C. krusei (N=50). C. glabrata isolates were screened for FKS mutations. All isolates were resistant clinically and/or in vitro to one or more standard antifungal compounds. VT-1161 and VT-1129 MICs for all isolates were at least 5-fold below achievable human plasma levels for VT-1161. VT-1161 and VT-1129 are promising for treatment of resistant C. glabrata and C. krusei infections.
December 12, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27927037/clinical-hepatotoxicity-associated-with-antifungal-agents
#20
Ioannis Kyriakidis, Athanasios Tragiannidis, Silke Munchen, Andreas H Groll
Invasive fungal diseases (IFDs) are a leading cause of morbidity and mortality among immunocompromised patients with bone marrow failure syndromes, hematological malignancies, hematopoietic stem cell transplantation (HSCT), those admitted in intensive care units (ICUs) and those with prolonged febrile neutropenia. IFDs occur in a setting of multiple morbidities and are associated with case fatality rates between 30 and 70%. Along with the development of classes and compounds, the last two decades have seen substantial improvements in the prevention and management of these infections and an overall increased use of antifungal agents...
December 16, 2016: Expert Opinion on Drug Safety
keyword
keyword
53131
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"